comprehensive
Thermo Fisher Scientific’s giant plant to manufacture gene therapies for drug companies is barely a year old, but executives at the maker of scientific tools are already talking about expanding.
Standing inside a cavernous unfinished section of the plant, Paul Fitzgerald, vice president and general manager of the site, told a group of biotech executives, journalists, and other visitors that he’s eager to transform it into laboratories. So far, the company is only using about 290,000 of the plant’s more than 400,000 square feet.
advertisement
“I look forward to you guys giving us a reason to fill up this space,” Fitzgerald quipped during a tour Tuesday of the plant.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
With competition flaring, obesity drug hits goal in liver disease study
Next article： Heart attack and stroke risk calculators need revising
Next article： Heart attack and stroke risk calculators need revising
